At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 41 enrolled
Drug / intervention
RO7062931 +1 moredrug
Likely dose
RO7062931 0.3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Sponsor-Open, Investigator-Blind, Subject-Blind, Placebo-Controlled, Single Ascending Dose, to Investigate the Safety, Tolerability and Pharmacokinetics of RO7062931 Following Subcutaneously Administration in Healthy Chinese Volunteers
In Brief
A Phase 1 clinical trial evaluating RO7062931 and Placebo for Healthy Participants. Completed, enrolled 41 participants across 2 sites.
Detailed Summary
This randomized study will evaluate the safety, tolerability and pharmacokinetics of single ascending subcutaneously administered doses of RO7062931 in healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesHong Kong
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartMay 2018
Primary CompletionJul 2019
TodayJul 2026
First PostedApr 23, 2018
Enrollment StartMay 3, 2018
Primary CompletionJul 5, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.2 years ago
Interventions
RO7062931drug
RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
Placebodrug
Matching placebo will be administered subcutaneously (SC).